CAS: 86-54-4; 1-Hydrazinylphthalazine

该化合物是一种主要用作治疗高血压的抗血压剂的药用化合物,它被归类为血管抑制剂,这意味着它通过放松血管,从而减少心脏工作量和降低血压发挥作用.氢氨的化学配方是C8H8N4, 并含有一种氢氨功能组,这有利于其行动机制. 氢甲氨通常是口服或静脉注射的,并经常与其他抗血压药物结合使用.它的药用植物包括肝脏的快速吸收和代谢,使个人半衰期变异.常见副作用可能包括头痛,热和胃肠扰动.由于它可能导致心血管反应和液体保留,因此它往往与糖尿病或乙型阻塞剂同时使用. 氢甲氨酸的使用通常与某些病人的药物诱发性脊髓红蛋白有关,在治疗期间需要谨慎监测,特别是在特定血压人群中,在具体治疗期间,主要动力水力管理中,仍然保留一种重要的高压.

结构式图片

欧盟法规

ECHA物质C&L通报REACH预注册

上下游产品

CAS号20062-41-3 3-甲基-1,2,4-噻唑并[...

合成工艺路线路线简述

  • 119-39-1 = 86-54-4
    反应条件:1.1 Reagents: Phosphorus Oxychloride; 2 Min,Rt2.1 Reagents: Hydrazine Hydrate (1:1) Solvents: Ethanol; 1 H,Rt
    标题:Identification Of New Potent Phthalazine Derivatives With Vegfr-2 And Egfr Kinase Inhibitory Activity
    作者:Amin,Kamilia M.; Et Al
    参考文献:European Journal Of Medicinal Chemistry 日期:2016 卷标:123 页码:191-201]

    119-39-1 = 86-54-4
    反应条件:1.1 Reagents: Phosphorus Oxychloride Solvents: Dichloromethane; 40 - 50 °C2.1 Reagents: Hydrazine Hydrate (1:1) Solvents: Ethanol; 78 °C
    标题:1,2,3-Triazolyl Pyrazole Derivatives As Anti-Cancer Agents: Biological Evaluation And Molecular Docking
    作者:Bhat,Manjunatha; Et Al
    参考文献:Pharma Chemica 日期:2016 卷标:8(19) 页码:200-221]

    119-67-5 = 86-54-4 [标题:Reaction Conditions
    标题:Product Class 10: Phthalazines
    作者:Haider,N.; Et Al
    参考文献:Science Of Synthesis 日期:2004 卷标:16 页码:315-372]

    2741-57-3 = 86-54-4 [标题:Reaction Conditions
    标题:Product Class 10: Phthalazines
    作者:Haider,N.; Et Al
    参考文献:Science Of Synthesis 日期:2004 卷标:16 页码:315-372]

    88491-65-0 = 86-54-4
    反应条件:1.1 Reagents: Hydrazine Solvents: Ethanol
    标题:Sn(Anrorc) Mechanism. Part 31. Hydrazination Of Pyridazines And Phthalazines
    作者:Counotte-Potman,A.; Et Al
    参考文献:Journal Of Heterocyclic Chemistry 日期:1983 卷标:20(5) 页码:1259-61]

    253-52-1 = 86-54-4
    反应条件:1.1 Reagents: Trichloroisocyanuric Acid Solvents: Dimethylformamide; 4 H,Rt -> 50 °C2.1 Reagents: Hydrazine Hydrate (1:1) Solvents: Ethanol; 5 H,Reflux
    标题:Synthesis And In Vitro Evaluation Of Hydrazinyl Phthalazines Against Malaria Parasite,Plasmodium Falciparum
    作者:Subramanian,Gowtham; Et Al
    参考文献:Bioorganic & Medicinal Chemistry Letters 日期:2016 卷标:26(14) 页码:3300-3306]

    119-67-5 = 86-54-4
    反应条件:1.1 Reagents: Hydrazine Hydrate (1:1); 1 H,Rt2.1 Reagents: Phosphorus Oxychloride; 2 Min,Rt3.1 Reagents: Hydrazine Hydrate (1:1) Solvents: Ethanol; 1 H,Rt
    标题:Identification Of New Potent Phthalazine Derivatives With Vegfr-2 And Egfr Kinase Inhibitory Activity
    作者:Amin,Kamilia M.; Et Al
    参考文献:European Journal Of Medicinal Chemistry 日期:2016 卷标:123 页码:191-201]

    3260-44-4 = 86-54-4 [标题:Reaction Conditions
    标题:Product Class 10: Phthalazines
    作者:Haider,N.; Et Al
    参考文献:Science Of Synthesis 日期:2004 卷标:16 页码:315-372]

    480-91-1 = 86-54-4 [标题:Reaction Conditions
    标题:Product Class 10: Phthalazines
    作者:Haider,N.; Et Al
    参考文献:Science Of Synthesis 日期:2004 卷标:16 页码:315-372

海关参考信息

专利信息


专利号:US-10925977-B2
优先权日:2006-10-05
标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
发明人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S
权利人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S; CEIL POINT LLC; UNIV TEXAS
摘要:Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.

专利号:US-2008287407-A1
优先权日:2003-12-10
标题 :Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use
发明人:GARVEY DAVID S; FANG XINQIN; KHANAPURE SUBHASH P; RANATUNGA RAMANI R; WEY SHIOW-JYI
权利人:NITROMED INC
摘要:The invention describes novel nitrosated and/or nitrosylated pyruvate compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated pyruvate compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one pyruvate compound and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one pyruvate compound, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating diseases resulting from oxidative stress, diabetes, reperfusion injury following ischemia, preservation of tissues, organs, organ parts and/or limbs.

专利号:US-7708989-B2
优先权日:1999-10-29
标题 :Methods of treating vascular diseases characterized by nitric oxide insufficiency
发明人:LOSCALZO JOSEPH; VITA JOSEPH A; LOBERG MICHAEL D; WORCEL MANUEL
权利人:NITROMED INC
摘要:The invention provides methods of treating and/or preventing vascular diseases characterized by nitric oxide insufficiency by administering a therapeutically effective amount of at least one nitrosated angiotensin-converting enzyme inhibitor, nitrosated beta-adrenergic blocker, nitrosated cholesterol reducer, nitrosated calcium channel blocker, nitrosated endothelin antagonist, nitrosated angiotensin II receptor antagonist, nitrosated renin inhibitor, and optionally at least one compound used to treat cardiovascular diseases and/or at least one antioxidant, or a pharmaceutically acceptable salt thereof, and/or at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase. The antioxidant may preferably be a hydralazine compound or a pharmaceutically acceptable salt thereof. The compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase may preferably be isosorbide dinitrate and/or isosorbide mononitrate. The vascular diseases characterized by nitric oxide insufficiency include a cardiovascular disease and a disease resulting from oxidative stress.

专利号:US-7220858-B2
优先权日:2003-12-23
标 题 :Synthesis of hydrazine and chlorinated derivatives of bicyclic pyridazines
发明人:NELSON DEANNA J
权利人:BARBEAU PHARMA INC
摘要:The present invention relates to both a novel method of preparing hydralazine hydrochloride and to a novel method of preparing hydrazine derivatives of compounds containing a pyridazine ring, including, for example, pyridazines, phthalazines and other compounds containing the pyridazine ring.

专利号:US-2008125354-A1
优先权日:2005-11-21
标题 :Selective inhibition of matrix metalloproteinases
发明人:FIELDS GREGG B; HAMMER ROBERT
权利人:UNIV FLORIDA ATLANTIC; UNIV LOUISIANA STATE
摘要:Synthetic triple-helical peptides (THPs) are used for the design and synthesis of triple-helical transition state analog inhibitors. These inhibitors feature a phosphonate ester or phosphinic moiety in place of the scissle bond. These groups inhibit MMPs, and methods been developed for their convenient incorporation within a peptide sequence by solid-phase methods.

专利号:US-8278296-B2
优先权日:2006-08-10
标题:Manipulation of brain CDP-diacylglycerol and uses thereof
发明人:UNDIEH ASHIWEL S
权利人:UNDIEH ASHIWEL S
摘要:Provided herein methods of screening for potential antidepressant compounds effective to increase production of cellular CDP-diacylglycerol and synthesis of inositol phospholipid in depression-related areas of the brain. Also, provided are methods of diagnosing and treating depressive or mood disorders in a subject by administering these screened antidepressant compounds. Further provided is a method of determining the therapeutic efficacy of an antidepressant drug regimen by comparing the ratio of CDP-diacylglycerol/inositol phosphate after treatment to a basal ratio in a subject.
上海富蔗化工有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.fuzhechem.com
企业联系电话:021-66402541,66402542,13901914741👤
📞上海富蔗化工有限公司 ⚠️参考联系方式
联系人:文君
电话:021-66402541,66402542,13901914741
手机:13901914741
传真:021-66402542
邮箱:2308653804@qq.com
通信地址: 上海市汶水路301号
邮编: 200442
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

地址:上海市汶水路301号
⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
第 1 / 1 页

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献


1: Nyolczas N, Dékány M, Muk B, Szabó B. Combination of Hydralazine and Isosorbide-Dinitrate in the Treatment of Patients with Heart Failure with Reduced Ejection Fraction. Adv Exp Med Biol. 2018;1067:31-45. doi: 10.1007/5584_2017_112. Review. doi: 10.1002/ar.23618. Epub 2017 Jul 25. doi: 10.1371/journal.pone.0158010. eCollection 2016.
4: Flynn JT, Bradford MC, Harvey EM. Intravenous Hydralazine in Hospitalized Children and Adolescents with Hypertension. J Pediatr. 2016 Jan;168:88-92. doi: 10.1016/j.jpeds.2015.07.070. Epub 2015 Sep 1. doi: 10.1097/MJT.0000000000000310. doi: 10.1007/s00467-014-2772-0. Epub 2014 Feb 20.

合成参考文献


参考文献:10.1007/s10165-010-0272-z|10.3109/s10165-010-0272-z
摘要:Matsuki Y, Sato K, Fujikawa A, Kyoto Y, Hashimoto H, Hakozaki Y. A case of incidentally detected IgG4-related sclerosing disease involving inflammatory abdominal aortic aneurysm and autoimmune pancreatitis. Mod Rheumatol. 2010 Jun;20(3):306–10. doi: 10.1007/s10165-010-0272-z.
参考文献:10.1038/labinvest.2011.92
摘要:Kao YH, Cheng CC, Chen YC, Chung CC, Lee TI, Chen SA, Chen YJ. Hydralazine-induced promoter demethylation enhances sarcoplasmic reticulum Ca2+ -ATPase and calcium homeostasis in cardiac myocytes. Lab Invest. 2011 Sep;91(9):1291–7. doi: 10.1038/labinvest.2011.92.
参考文献:10.1007/s12028-011-9593-9
摘要:Wolf S; Participants in the International Multi-Disciplinary Consensus Conference on the Critical Care Management of Subarachnoid Hemorrhage. Routine management of volume status after aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2011 Sep;15(2):275–80. doi: 10.1007/s12028-011-9593-9.
参考文献:10.1186/1472-6963-11-167
摘要:de Vries AE, de Jong RM, van der Wal MH, Jaarsma T, van Dijk RB, Hillege HL. The value of INnovative ICT guided disease management combined with Telemonitoring in OUtpatient clinics for Chronic Heart failure patients. Design and methodology of the IN TOUCH study: a multicenter randomised trial. BMC Health Services Research. 2011 Jul 13;11(1):167. doi: 10.1186/1472-6963-11-167.
参考文献:10.1007/s00467-011-1964-0
摘要:Chandar J, Zilleruelo G. Hypertensive crisis in children. Pediatr Nephrol. 2012 May;27(5):741–51. doi: 10.1007/s00467-011-1964-0.
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知